Hepatic encephalopathy (HE) is a severe complication of TIPS treatment in patients with cirrhosis and variceal bleeding. Lactulose, is considered the first-line therapeutic agent for treating hepatic encephalopathy. Based on route of administration, Hepatic Encephalopathy Drugs include oral (tablets & solutions) and injections.
This report contains market size and forecasts of Hepatic Encephalopathy Drugs in global, including the following market information:
Global Hepatic Encephalopathy Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Hepatic Encephalopathy Drugs Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Hepatic Encephalopathy Drugs companies in 2021 (%)
The global Hepatic Encephalopathy Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Injection Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hepatic Encephalopathy Drugs include ASKA Pharmaceutical, Cosmo Pharmaceuticals, Bausch Health, Ferring Pharmaceuticals, Mallinckrodt, Umecrine Cognition, Norgine, Lupin and Kaleido Biosciences and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hepatic Encephalopathy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hepatic Encephalopathy Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Hepatic Encephalopathy Drugs Market Segment Percentages, by Type, 2021 (%)
Injection
Oral
Global Hepatic Encephalopathy Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Hepatic Encephalopathy Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hepatic Encephalopathy Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Hepatic Encephalopathy Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hepatic Encephalopathy Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Hepatic Encephalopathy Drugs revenues share in global market, 2021 (%)
Key companies Hepatic Encephalopathy Drugs sales in global market, 2017-2022 (Estimated), (MT)
Key companies Hepatic Encephalopathy Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
ASKA Pharmaceutical
Cosmo Pharmaceuticals
Bausch Health
Ferring Pharmaceuticals
Mallinckrodt
Umecrine Cognition
Norgine
Lupin
Kaleido Biosciences
Kannalife Sciences